References
- Mandell WF, Garvey GJ, Neu HC. Achromobacter xylosoxidans bacteremia. Rev Infect Dis 1987;9:1001-5 https://doi.org/10.1093/clinids/9.5.1001
- Aisenberg G, Rolston KV, Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 2004;101:2134-40 https://doi.org/10.1002/cncr.20604
- Gomez-Cerezo J, Suarez I, Rios JJ, Pena P, Garcia de Miguel MJ, de Jose M, et al. Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases. Eur J Clin Microbiol Infect Dis 2003;22:360-3 https://doi.org/10.1007/s10096-003-0925-3
- Kish MA, Buggy BP, Forbes BA. Bacteremia caused by Achromobacter species in an immunocompromised host. J Clin Microbiol 1984;19:947-8
- Knippschild M, Schmid EN, Uppenkamp M, Konig E, Meusers P, Brittinger G, et al. Infection by Alcaligenes xylosoxidans subsp. xylosoxidans in neutropenic patients. Oncology 1996;53:258-62 https://doi.org/10.1159/000227570
- Legrand C, Anaissie E. Bacteremia due to Achromobacter xylosoxidans in patients with cancer. Clin Infect Dis 1992;14:479-84 https://doi.org/10.1093/clinids/14.2.479
- Mizunoe S, Yamasaki T, Hirai K, Yamagata E, Hiramatsu K, Yamakami Y, et al. Case report: subcutaneous abscess and thoracic empyema caused by Alcaligenes xylosoxidans. Kansenshogaku Zasshi 1998;72:631-4
- Shie SS, Huang CT, Leu HS. Characteristics of Achromobacter xylosoxidans bacteremia in northern Taiwan. J Microbiol Immunol Infect 2005;38:277-82
- Tsay RW, Lin LC, Chiou CS, Liao JC, Chen CH, Liu CE, et al. Alcaligenes xylosoxidans bacteremia: clinical features and microbiological characteristics of isolates. J Microbiol Immunol Infect 2005;38:194-9
- Weitkamp JH, Tang YW, Haas DW, Midha NK, Crowe JE Jr. Recurrent Achromobacter xylosoxidans bacteremia associated with persistent lymph node infection in a patient with hyper-immunoglobulin M syndrome. Clin Infect Dis 2000;31:1183-7 https://doi.org/10.1086/317461
- Igra-Siegman Y, Chmel H, Cobbs C. Clinical and laboratory characteristics of Achromobacter xylosoxidans infection. J Clin Microbiol 1980;11:141-5
- De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 2007;6:75-8 https://doi.org/10.1016/j.jcf.2006.05.011
- Vay CA, Almuzara MN, Rodriguez CH, Pugliese ML, Lorenzo Barba F, Mattera JC, et al. 'In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp. Rev Argent Microbiol 2005;37:34-45
- Spear JB, Fuhrer J, Kirby BD. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a well-water source: case report and review of the literature. J Clin Microbiol 1988;26:598-9
- Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes 3xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002;46:1105-7 https://doi.org/10.1128/AAC.46.4.1105-1107.2002